6th Annual Somatic Cell Therapy Symposium Tissue & IND Products

Size: px
Start display at page:

Download "6th Annual Somatic Cell Therapy Symposium Tissue & IND Products"

Transcription

1 6th Annual Somatic Cell Therapy Symposium Tissue & IND Products September 27, 2006 D. Michael Strong PhD, BCLD(ABB)

2 Puget Sound Blood Center Northwest Tissue Center 10 Donor Centers Bellevue Central Seattle North Seattle Tukwila Bellingham Everett Lynnwood Olympia Silverdale Vancouver 4 Laboratories Bellevue Central Seattle University District Renton

3 Seattle 921 Terry Avenue Headquarters Administrative Laboratory Services

4 Renton Testing & Tissue Processing

5 Puget Sound Blood Center PRODUCTS AND SERVICES Red Cells 173,618 Plasma FFP 57,398 Recovered 113,375 Platelets WBP 41,591 Apheresis 18,852 Donor Testing* 434,787 Lab Services* 17,750 Transfusion Service 650,115 Patient Services* 4,697 * Tests/procedures performed per year

6 Northwest Tissue Center TISSUE RECOVERY AND PROCESSING Skin 1,245 Fascia 23 Tendons 1,900 Bone 7,000 Heart Valves 46 Stem Cells 90 Cord Blood 1,067 Islet Cells 13

7

8 Regulatory Organizational FDA OSHA DOL CLIA Washington NRC Washington Homeland Security IATA International Air Transport Assoc. RCW Revised Code of Washington WAC Washington Administration Code FAA Federal Aviation Association DOT Department of Transportation

9 Regulatory Product INDs Tissue/Cellular Therapy Blood Products Islet Cells / IND on a consultant basis for ITN Cord Blood / IND NMDP, AABB and/or FACT

10 Accreditation / Licensing Organizational Voluntary AABB - Transfusion Activities - Donor Center Activities - Hematopoietic Progenitor Cells (HCP) Activities - Cord Blood Activities - IRL Activities ASHI Non-voluntary EU ZLB Octapharma WA State Pharmacy Board California (CLIA) WMTS WA Medical Test Site

11 Accreditation / Licensing Product Tissue / Cell Therapy AABB Cellular Therapy AATB NMDP Cord Blood State of Illinois State of New York State of California State of Florida Islets / IND JDRF Juvenile Diabetes Research Foundation (Distribution of Islets for Research) ITN Immune Tolerance Network ICR Islet Cell Resource

12 Islet IND Islet Alone IA Sponsor: ITN Immune Tolerance Network Transplant Center: Virginia Mason University of Washington Swedish Medical Center Simultaneous Kidney / Islet - SKI Sponsor: Puget Sound Blood Center Islet After Kidney - IAK Sponsor: Puget Sound Blood Center Transplant Center: Virginia Mason Transplant Center: Swedish Medical Center Site inspection and trial pancreas isolations completed prior to site activation for IND. Laboratory was responsible for processing and documentation of the processing events. Site was inspected by CRO for adherence to protocol.

13 Cord Blood IND Sponsor: National Marrow Donor Program NMDP inspects cord blood banks and transplant centers prior to participation AABB and/or FACT accreditation required Quality Requirements - Sample availability - Donor assessment - Product quality reporting (ie. cell counts, CFU, viability, etc.) 16 participating banks around the country with almost 50,000 units available. 166 transplantation centers affiliated with NMDP are able to receive cord blood. 206 cord blood units shipped in the first half of 2006, 8 of those from PSBC / NTC.

14 Strategies Preparing for an inspection Preparation is never ending!!!!

15 Challenges Differences Frequency AABB once every 2 years AATB once every 3 years FDA once a year alternately between facilities Approach AABB Quality Systems approach Self-assessment tool is sent when standards change (survey) AATB Checklist approach S.T.A.R. Self-assessment Tool / Audit Report (checklist) FDA Guidance approach

16 Strategies Preparing for an inspection OR Against standards & regulations Internal auditing Conduct a gap analysis Measure compliance with existing processes Conduct one year prior to inspection date External auditing Contract independent assessor for pre-assessment Deficiencies Create corrective action plan & timeline Deficiencies from previous inspections are top priority

17 Strategies Preparing for an inspection Scheduling the inspection Understand the scope of the inspection What will they be looking at? Who will be arriving? With what companies are they professionally affiliated? How long do they plan to be there? Is there a list of documents that can be provided on their arrival? Whose coming when?!? With FDA you never know.

18 Strategies In house preparation Designate an inspection team These individuals are liaisons to the investigator Liaisons will be running the show Play the role of scribe and document each day Develop working relationship with the inspector Be knowledgeable of processes, standards, & regulations Know how and who to contact for answers to obscure questions Ensure access to information Review documents prior to providing to inspector

19 Strategies Inform participants and convey expectations Professionalism Short direct answers Don t guess - I don t know. Let me get back to you. - Don t speculate or give personal opinions List of requested documents - Have QA review for completeness and accuracy Stay focused on critical tasks

20 Uh-oh their here!! Stay calm and have faith that trained people will get the job done right!

Sharon Tindle, MS, CQA (ASQ) QA Manager, BMT Tissue Services Mount Sinai Hospital, New York, NY. June 7, 2016

Sharon Tindle, MS, CQA (ASQ) QA Manager, BMT Tissue Services Mount Sinai Hospital, New York, NY. June 7, 2016 Sharon Tindle, MS, CQA (ASQ) QA Manager, BMT Tissue Services Mount Sinai Hospital, New York, NY June 7, 2016 1 Brief description of the Mount Sinai Cellular Therapy Laboratory Overview of BM transplant

More information

Inspections, Compliance, Enforcement, and Criminal Investigations

Inspections, Compliance, Enforcement, and Criminal Investigations Page 1 of 5 Home Inspections, Compliance, Enforcement, and Criminal Investigations Enforcement Actions Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations Puget Sound Blood

More information

Cell Therapy Liaison Meeting, June 16, 2006

Cell Therapy Liaison Meeting, June 16, 2006 Cell Therapy Liaison Meeting, June 16, 2006 Host Organization Original Agenda Moderator: Stephen J. Noga, MD, PhD 1:00-1:15 Call to Order and Introduction of agenda and meeting participants Review of Summary

More information

Regulatory Issues in Human Subjects Research

Regulatory Issues in Human Subjects Research Regulatory Issues in Human Subjects Research Ian McNiece, PhD University of Miami Human Subjects Research Require IRB approval Studies of new drugs or applications of drugs require an FDA approved IND

More information

Stem Cell Uses and FDA Regulation

Stem Cell Uses and FDA Regulation Stem cells have been called everything from cure-alls to miracle treatments. But don t believe the hype. Some unscrupulous providers offer stem cell products that are both unapproved and unproven. So beware

More information

EXAMPLE OF VENDOR QUALIFICATION FOR IMMUNE EFFECTOR CELL PRODUCT MANUFACTURER

EXAMPLE OF VENDOR QUALIFICATION FOR IMMUNE EFFECTOR CELL PRODUCT MANUFACTURER EXAMPLE OF VENDOR QUALIFICATION FOR IMMUNE EFFECTOR CELL PRODUCT MANUFACTURER Disclaimer: This example is just one potential example of a vendor qualification form to verify the adequacy of the internal

More information

Common AABB Assessment Findings

Common AABB Assessment Findings Common AABB Assessment Findings Linda Sigg, MT(ASCP)SBB, CQA(ASQ) Staff Lead Assessor, Accreditation and Quality AABB Southeastern Area Blood Bankers Association Annual Meeting March 4-5, 2009 Introduction

More information

FDA Approach to the Regulation of Hematopoietic Stem/Progenitor Cells (HPC)

FDA Approach to the Regulation of Hematopoietic Stem/Progenitor Cells (HPC) FDA Approach to the Regulation of Hematopoietic Stem/Progenitor Cells (HPC) Ellen Lazarus, M.D. Medical Officer Division of Human Tissues Office of Cellular, Tissue, and Gene Therapies FDA proposed approach

More information

Safa Karandish Office of Tissues and Advanced Therapies Division of Human Tissues. Pharma Conference February

Safa Karandish Office of Tissues and Advanced Therapies Division of Human Tissues. Pharma Conference February Safa Karandish Office of Tissues and Advanced Therapies Division of Human Tissues Pharma Conference February 2017 1 Background HCT/P regulatory framework Definitions & exceptions Establishment registration-

More information

Starting from Scratch: Experiences with a Focused Apheresis Service

Starting from Scratch: Experiences with a Focused Apheresis Service Starting from Scratch: Experiences with a Focused Apheresis Service University of Virginia Tamila Kindwall-Keller, DO, MS September 21, 2018 Disclosures Medical Monitor for BMT CTN 1301 Back Up Medical

More information

TITLE: Extended Storage of Pathogen-Reduced Platelet Concentrates (PRECON) Seattle, WA 98104

TITLE: Extended Storage of Pathogen-Reduced Platelet Concentrates (PRECON) Seattle, WA 98104 AWARD NUMBER: W81XWH-13-2-0089 TITLE: Extended Storage of Pathogen-Reduced Platelet Concentrates (PRECON) PRINCIPAL INVESTIGATOR: Sherrill J. Slichter, MD CONTRACTING ORGANIZATION: Puget Sound Blood Center

More information

Challenges In Cell Product Labeling, Tracking And Traceability

Challenges In Cell Product Labeling, Tracking And Traceability Challenges In Cell Product Labeling, Tracking And Traceability April 4-5, 2008 Columbus, Ohio Dave Krugh, MT(ASCP)SBB, CLS,CLCP(NCA) Clinical Program Manager, BMT Program Clinical Instructor, Department

More information

Quality Management. Carlos Bachier, MD

Quality Management. Carlos Bachier, MD Quality Management Carlos Bachier, MD Goals of Quality Management Ensure credibility of outcomes Improve patient safety and quality of processes Significantly reduce errors Quality Medical and Laboratory

More information

Mesenchymal Stromal Cells Large-scale Culture

Mesenchymal Stromal Cells Large-scale Culture Mesenchymal Stromal Cells Large-scale Culture Adrian Gee Center for Cell & Gene Therapy Baylor College of Medicine Houston, Texas Hanley et al: Efficient manufacturing of therapeutic mesenchymal stromal

More information

07/30/2013. Record of Revisions IRB Page 1 of 17

07/30/2013. Record of Revisions IRB Page 1 of 17 Current Protocol Version 7.1 (Continuing Review) Approved July 30, 2013 Version 7.1 (Amendment) September 6, 2012 Version 7.0 (Continuing Review) July 30, 2012 Version 6.0 (Continuing Review) July 30,

More information

CTLM Cell Therapy Liaison Meetings

CTLM Cell Therapy Liaison Meetings CTLM Cell Therapy Liaison Meetings October 2 nd, 2016 Olive J. Sturtevant, MHP, MT(ASCP)SBB,SLS, CQA(ASQ), CTLM Lead Designate, ISCT North America Legal & Regulatory Affairs Committee Mission of CTLM To

More information

Human Tissue Intended for Transplantation Skin, corneas, sclera, bone, heart valves, blood vessels, pericardium, tendons, cartilage, fascia

Human Tissue Intended for Transplantation Skin, corneas, sclera, bone, heart valves, blood vessels, pericardium, tendons, cartilage, fascia TITLE / DESCRIPTION: DEPARTMENT: Human Tissue Intended for Transplantation Skin, corneas, sclera, bone, heart valves, blood vessels, pericardium, tendons, cartilage, fascia Surgical Services PERSONNEL:

More information

FDA Inspections: FDA Inspections: An Overview Overview

FDA Inspections: FDA Inspections: An Overview Overview FDA Inspections: An Overview Robert Lindblad, MD The EMMES Corporation August 11, 2011 researchcartoons.com Why Inspections? Why Inspections? To evaluate compliance with regulations To establish that an

More information

UDI Guidance Document for Medical Devices Containing HCT/P

UDI Guidance Document for Medical Devices Containing HCT/P LEARNING UDI COMMUNITY UDI Guidance Document for Medical Devices Containing HCT/P WWW.AHRMM.ORG / LUC INTRODUCTION: Human cells, tissues, or cellular or tissue-based products (HCT/Ps) are a precious resource

More information

FAQ ABOUT. 21CFR Part 1271 FDA REGULATION OF REPRODUCTIVE TISSUE LABS

FAQ ABOUT. 21CFR Part 1271 FDA REGULATION OF REPRODUCTIVE TISSUE LABS FAQ ABOUT 21CFR Part 1271 FDA REGULATION OF REPRODUCTIVE TISSUE LABS XYTEX INTERNATIONAL, LTD. AUGUSTA, GEORGIA NOVEMBER 2005 Xytex International, 2005 Xytex is a registered trademark of Xytex International,

More information

FACT - CIBMTR Data Audit Collaboration

FACT - CIBMTR Data Audit Collaboration FACT - CIBMTR Data Audit Collaboration Phyllis I. Warkentin, MD FACT Chief Medical Officer February 2017 FACT-CIBMTR Data Audit Collaboration History of data audits The joint FACT-CIBMTR Task Force becomes

More information

CELLULAR THERAPY PRODUCT COLLECTION, PROCESSING, AND ADMINISTRATION ACCREDITATION MANUAL

CELLULAR THERAPY PRODUCT COLLECTION, PROCESSING, AND ADMINISTRATION ACCREDITATION MANUAL CELLULAR THERAPY PRODUCT COLLECTION, PROCESSING, AND ADMINISTRATION ACCREDITATION MANUAL Guidance Document to Accompany the FACT-JACIE International Standards for Cellular Therapy Product Collection, Processing

More information

Stem Cells, Regenerative Medicine and cgmp (GTP)

Stem Cells, Regenerative Medicine and cgmp (GTP) Stem Cells, Regenerative Medicine and cgmp (GTP) Encompass Stem cell based therapies activities Collection source Purification Isolation from other cell types if needed Manipulation Minimal vs Moderate

More information

Patient Handbook on Stem Cell Therapies

Patient Handbook on Stem Cell Therapies Patient Handbook on Stem Cell Therapies WWW.ISSCR.ORG WWW.CLOSERLOOKATSTEMCELLS.ORG Patient Handbook on Stem Cell Therapies Introduction We have all heard about the extraordinary promise that stem cell

More information

The New News in Stem Cell Research Andrés Bratt-Leal, PhD 12/1/2017

The New News in Stem Cell Research Andrés Bratt-Leal, PhD 12/1/2017 The New News in Stem Cell Research Andrés Bratt-Leal, PhD 12/1/2017 Cell Therapy and Parkinson s Disease Very specific neural degeneration >50% of DA neurons are gone by diagnosis 1 million in the USA,

More information

Reporting Deviations of Biological Products and HCT/Ps. Ellen Areman Senior Consultant Biologics Consulting Group, Inc.

Reporting Deviations of Biological Products and HCT/Ps. Ellen Areman Senior Consultant Biologics Consulting Group, Inc. Reporting Deviations of Biological Products and HCT/Ps Ellen Areman Senior Consultant Biologics Consulting Group, Inc. Relevant Legislation Public Health Service (PHS) Act Regulates biological products

More information

IDE Submissions for Devices Used to Manufacture Cell Therapy Products

IDE Submissions for Devices Used to Manufacture Cell Therapy Products IDE Submissions for Devices Used to Manufacture Cell Therapy Products Janice Davis-Sproul, MAS Johns Hopkins Medicine 7 th Annual Somatic Cell Therapy Symposium 1 Overview Discuss an investigatorsponsored

More information

Stem Cell Research 101

Stem Cell Research 101 Stem Cell Research : A promising type of bioscience research The Stem Cell debate and the impact of the induced pluripotent stem cell procedure Why Is Vocabulary Important? Key terms frame the debate Mature

More information

Summary of Accomplishments

Summary of Accomplishments Summary of Accomplishments July 1, 2012 June 30, 2013 The CIBMTR network comprises more than 300 centers across the globe. Mission To improve the outcomes of hematopoietic stem cell transplantation (HCT)

More information

MOLLY STEVENS Regeneration

MOLLY STEVENS Regeneration MOLLY STEVENS Regeneration ABOUT ME When I was a student, the idea of taking a skin cell (outpatient procedure) and turning it into brain stem cell was an idea that would have been heresy. It s real today.

More information

Cell Therapy Liaison Meeting, June 24, 2005

Cell Therapy Liaison Meeting, June 24, 2005 Cell Therapy Liaison Meeting, June 24, 2005 Host Organization Agenda Moderator: Stephen J. Noga, MD, PhD 8:30-8:45 -- Introduction of FDA and Industry participants -- Review of Summary & Action Items from

More information

ISBT 128 Labeling Overview. Fran Rabe University of Minnesota Molecular and Cellular Therapeutics

ISBT 128 Labeling Overview. Fran Rabe University of Minnesota Molecular and Cellular Therapeutics ISBT 128 Labeling Overview Fran Rabe University of Minnesota Molecular and Cellular Therapeutics ICCBBA u Not for profit organization u Formally: International Council for Commonality in Blood Banking

More information

Lesson 7A Specialized Cells, Stem Cells & Cellular Differentiation

Lesson 7A Specialized Cells, Stem Cells & Cellular Differentiation Lesson 7A Specialized Cells, Stem Cells & Cellular Differentiation Learning Goals I can explain the concept of cell differentiation and cell specialization. I can explain how the cell structure relates

More information

How Data Managers Support Prospective Research

How Data Managers Support Prospective Research How Data Managers Support Prospective Research CIBMTR Data Managers Meeting February 20, 2018 Hati Kobusingye & Deborah Mattila Prospective Clinical Research Agenda Background - Prospective Research (RCI

More information

First Place Essay. Katie P.

First Place Essay. Katie P. First Place Essay Katie P. Eighth Grade West Reading, PA 19611 Bioscience research is seeking information by exploring life's processes and diseases. It has helped many scientists understand how the body

More information

CBER Regulation of Devices for Cell Therapy

CBER Regulation of Devices for Cell Therapy CBER Regulation of Devices for Cell Therapy Richard D. McFarland, Ph.D., M.D. Associate Director for Policy Office of Cellular, Tissue and Gene Therapies Center for Biologics Evaluation and Research Food

More information

Cellular and Gene Therapy Products - CBER Update

Cellular and Gene Therapy Products - CBER Update DEPARTMENT OF HEALTH AND HUMAN SERVICES CENTER FOR BIOLOGICS EVALUATION and RESEARCH Cellular and Gene Therapy Products - CBER Update Well Characterized Biological Products January 12-14, 2009 Kimberly

More information

Paul Ashford Executive Director ICCBBA

Paul Ashford Executive Director ICCBBA Introduction to ISBT 128 Paul Ashford Executive Director ICCBBA ICCBBA ICCBBA enhances safety for patients by managing the ISBT 128 international information standard for use in transfusion and transplantation.

More information

INTERNATIONAL STANDARDS FOR CELLULAR THERAPY PRODUCT COLLECTION, PROCESSING, AND ADMINISTRATION

INTERNATIONAL STANDARDS FOR CELLULAR THERAPY PRODUCT COLLECTION, PROCESSING, AND ADMINISTRATION INTERNATIONAL STANDARDS FOR CELLULAR THERAPY PRODUCT COLLECTION, PROCESSING, AND ADMINISTRATION Fifth Edition Version 5.1 March 2012 NOTICE These Standards are designed to provide minimum guidelines for

More information

Sharing Data: Recovering Registry Addict

Sharing Data: Recovering Registry Addict Sharing Data: Observations From a Recovering Registry Addict Christopher Bredeson, MD, MSc., FRCPC Director, Hematologic Malignancies Professor of Medicine Medical College of Wisconsin DBV06_1.ppt TODAY

More information

Research Study Comparison of. Angel Whole Blood Separation System and EmCyte PurePRP

Research Study Comparison of. Angel Whole Blood Separation System and EmCyte PurePRP Research Study Comparison of Angel Whole Blood Separation and EmCyte PurePRP Prepared by Robert Mandle, PhD Biosciences Research Associates Cambridge, MA Study Date March 6, 2014 Contents 1. Introduction

More information

10-CBA providing access to unlicensed cord blood units

10-CBA providing access to unlicensed cord blood units 10-CBA providing access to unlicensed cord blood units Using the NMDP IND to access unlicensed cord blood units Amy Hays, Sr. Clinical Research Specialist, CIBMTR History of CBUs First CBU transplant done

More information

Terminology Group. Cellular Therapy Coding & Labeling Advisory Group

Terminology Group. Cellular Therapy Coding & Labeling Advisory Group Terminology Group Task Group Members Alan Lankester Pat Distler Derwood Pamphilon Leigh Poston Kathy Loper Ineke Slaper-Cortenbach Phyllis Warkentin Assignment Review existing definitions in ISBT 128 data

More information

Production Assistance for Cellular Therapies PACT

Production Assistance for Cellular Therapies PACT Production Assistance for Cellular Therapies PACT Traci Heath Mondoro, PhD NHLBI Bethesda, Maryland Renewed PACT Program Renewed January 15, 2010 Scope and size expanded Cell Processing Facilities (CPFs)

More information

Cell Processing at CAGT. Overview. Adrian P. Gee Center for Cell & Gene Therapy. CAGT Introduction

Cell Processing at CAGT. Overview. Adrian P. Gee Center for Cell & Gene Therapy. CAGT Introduction Cell Processing at CAGT Adrian P. Center for Cell & Gene Therapy CAGT Introduction Overview Facility Description Products prepared Flow cytometry Quality Control Quality Assurance 1 Center for Cell & Gene

More information

FACT Inspector Standards Review Questions 5 th Edition Cord Blood Standards

FACT Inspector Standards Review Questions 5 th Edition Cord Blood Standards FACT Inspector Standards Review Questions 5 th Edition Cord Blood Standards Inspector Name: Note: A score of 90% or higher is required to achieve active inspector status. Inspector Techniques 1. As a FACT

More information

Celluvative. Cellular Therapies Redefined. A portfolio of products and services brought to you by: Saving lives today. Improving life tomorrow.

Celluvative. Cellular Therapies Redefined. A portfolio of products and services brought to you by: Saving lives today. Improving life tomorrow. Cellular Therapies Redefined A portfolio of products and services brought to you by: Saving lives today. Improving life tomorrow. cell u va tive / sel-yoo-vā-tiv/ noun 1. a partnership between BloodCenter

More information

Expert in biological products of human origin BLOOD PRODUCTS STABLE PRODUCTS STEM CELLS HUMAN TISSUES MOTHER S MILK

Expert in biological products of human origin BLOOD PRODUCTS STABLE PRODUCTS STEM CELLS HUMAN TISSUES MOTHER S MILK BLOOD PRODUCTS STABLE PRODUCTS STEM CELLS HUMAN TISSUES MOTHER S MILK Rosalie makes her first apheresis plasma donation. Expert in biological products of human origin 2016 2017 ACTIVITY REPORT MISSION

More information

FDA Regulatory, Compliance and Policy Developments: 361 HCT/Ps

FDA Regulatory, Compliance and Policy Developments: 361 HCT/Ps FDA Regulatory, Compliance and Policy Developments: 361 HCT/Ps September 27, 2018 Presentation by: Elaine H. Tseng Partner FDA and Life Sciences Group King & Spalding Discussion with: Thomas Poché Vice

More information

Precision Biospecimen Solutions: Paving the Way to Personalized Medicine

Precision Biospecimen Solutions: Paving the Way to Personalized Medicine Precision Biospecimen Solutions: Paving the Way to Personalized Medicine ACCELERATING RESEARCH. IMPROVING OUTCOMES. The companies under the Precision for Medicine banner deliver specialized strategic and

More information

The transfer of all HPC products should be transferred to and from the courier in a clinical setting.

The transfer of all HPC products should be transferred to and from the courier in a clinical setting. INTRODUCTION The WMDA is a worldwide network of organisations that provide haematopoietic progenitor cells (HPC) from voluntary unrelated donors to those in need of hematopoietic stem cell transplantation.

More information

Regulation of Biologics in The United States: From a Rich Tradition To A Challenging Future

Regulation of Biologics in The United States: From a Rich Tradition To A Challenging Future Regulation of Biologics in The United States: From a Rich Tradition To A Challenging Future Chris Joneckis,, Ph.D. Senior Advisor For CMC Issues Center For Biologics Evaluation And Research Food and Drug

More information

Stem Cell Transport in 2013: Introducing the Credo Cooler to TOH BMT Program

Stem Cell Transport in 2013: Introducing the Credo Cooler to TOH BMT Program Stem Cell Transport in 2013: Introducing the Credo Cooler to TOH BMT Program Carey Landry, PhD Program Analyst The Ottawa Hospital Blood and Marrow Transplant Program Why Change Coolers? Need to take advantage

More information

HCT/P Deviations & Reporting. 13 th ANNUAL FDA & The Changing Paradigm for HCT/P Regulation February 13-15, 2017

HCT/P Deviations & Reporting. 13 th ANNUAL FDA & The Changing Paradigm for HCT/P Regulation February 13-15, 2017 HCT/P Deviations & Reporting CASE STUDIES FROM TISSUE AND EYE BANKS AND CELLULAR THERAPY. 13 th ANNUAL FDA & The Changing Paradigm for HCT/P Regulation February 13-15, 2017 Tissue Bank Perspective Ashley

More information

Hematopoietic Progenitor Cell Product Characterization

Hematopoietic Progenitor Cell Product Characterization Hematopoietic Progenitor Cell Product Characterization Carolyn A. Taylor, Ph.D. Professor of Medicine Director of BMT Program Cell Processing Laboratory Product Testing and Characterization Goals Required

More information

Inspections, Compliance, Enforcement, and Criminal Investigations

Inspections, Compliance, Enforcement, and Criminal Investigations Page 1 of 5 Home Inspections, Compliance, Enforcement, and Criminal Investigations Enforcement Actions Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations Thomas E. Young,

More information

Des cellules-souches dans le poumon : pourquoi faire?

Des cellules-souches dans le poumon : pourquoi faire? Des cellules-souches dans le poumon : pourquoi faire? Karl-Heinz Krause Dept. of Pathology and Immunology, Medical Faculty Dept. of Genetic and Laboratory Medicine, University Hospitals Geneva, Switzerland

More information

IND - Cell Therapy. Robert W. Lindblad, MD, FACEP. Where Did you Hear

IND - Cell Therapy. Robert W. Lindblad, MD, FACEP. Where Did you Hear IND - Cell Therapy Robert W. Lindblad, MD, FACEP Where Did you Hear The EMMES Corporation CRO Coordinating Center Cell Therapy PACT Production Assistance for Cellular Therapy Bone Marrow Transplant Network

More information

"From Bedside to Bench and Back: regulatory requirements for collaborations between pharma industry and academia

From Bedside to Bench and Back: regulatory requirements for collaborations between pharma industry and academia "From Bedside to Bench and Back: regulatory requirements for collaborations between pharma industry and academia Damir Hamamdžić D.V.M., Ph.D. Office of Research Regulatory Affairs Rutgers University RWJMS

More information

FDA Perspective on Plasma Quality and GMPs

FDA Perspective on Plasma Quality and GMPs FDA Perspective on Plasma Quality and GMPs Judy Ellen Ciaraldi Food and Drug Administration Division of Blood Components & Devices/OBRR/CBER IPFA/BCA Global Symposium September 23, 2014 Sacramento, California

More information

Quality Management Plan for Collections. ISCT Annual Meeting May 24, 2010 Renee Smilee, MT(ASCP) Cell Therapy Manager Moffitt Cancer Center

Quality Management Plan for Collections. ISCT Annual Meeting May 24, 2010 Renee Smilee, MT(ASCP) Cell Therapy Manager Moffitt Cancer Center Quality Management Plan for Collections ISCT Annual Meeting May 24, 2010 Renee Smilee, MT(ASCP) Cell Therapy Manager Moffitt Cancer Center Cost of Quality This is not the price of creating the quality

More information

Characteristics. Capable of dividing and renewing themselves for long periods of time (proliferation and renewal)

Characteristics. Capable of dividing and renewing themselves for long periods of time (proliferation and renewal) STEM CELLS (p 2-8) Overview The body is made up of about 200 different kinds of specialised cells, such as muscle cells, nerve cells, fat cells and skin cells. Cells with the capacity to give rise to the

More information

Oncology for Scientists Christopher Choi, PhD Director, TCPF Assistant Professor of Oncology

Oncology for Scientists Christopher Choi, PhD Director, TCPF Assistant Professor of Oncology Oncology for Scientists Christopher Choi, PhD Director, TCPF Assistant Professor of Oncology Immunological Battle Ground Tumor immunity Tumor growth The tumor environment is an immunological battle ground:

More information

Pre Pre-IND and Pre-IND Interactions for Cell and Gene Therapy Products

Pre Pre-IND and Pre-IND Interactions for Cell and Gene Therapy Products Pre Pre-IND and Pre-IND Interactions for Cell and Gene Therapy Products Theresa Chen, PhD Division of Clinical Evaluation and Pharmacology/Toxicology (DCEPT) Office of Tissues and Advanced Therapies (OTAT)

More information

Andrew Finnerty General Manager - CCMI

Andrew Finnerty General Manager - CCMI Andrew Finnerty General Manager - CCMI Manufacturing Human Mesenchymal Stem Cells for Clinical Trials Quality Considerations Biopharma and Pharma RQA Regional Forum Bioclin Laboratories, Athlone 13 May

More information

Apheresis M. Flores, BSN, RN, HP (ASCP)

Apheresis M. Flores, BSN, RN, HP (ASCP) Apheresis M. Flores, BSN, RN, HP (ASCP) Objectives: 1. Discuss Apheresis and key concepts 2. Discuss : Cell Collection Extracorporeal Photopheresis (ECP) 1 What is Apheresis? Apheresis: Greek word meaning

More information

Point-of-Care Cell Processing Devices A Manufacturer s Perspective Clinical trials, regulatory compliance, and commercialization.

Point-of-Care Cell Processing Devices A Manufacturer s Perspective Clinical trials, regulatory compliance, and commercialization. Philadelphia, 2013 Point-of-Care Cell Processing Devices A Manufacturer s Perspective Clinical trials, regulatory compliance, and commercialization. Brian Barnes, Ph.D. VP, Clinical and Regulatory Affairs

More information

Challenges in Capturing Long Term Follow up of Recipients of Genetically Modified Cells. Cell Therapy Liaison Meeting January, 2018

Challenges in Capturing Long Term Follow up of Recipients of Genetically Modified Cells. Cell Therapy Liaison Meeting January, 2018 Challenges in Capturing Long Term Follow up of Recipients of Genetically Modified Cells Cell Therapy Liaison Meeting January, 2018 Outline Development of the Cellular Therapy Registry Standardized Data

More information

FDA Update. Scott A. Brubaker, CTBS Director, Division of Human Tissues Office of Tissues and Advanced Therapies CBER/FDA

FDA Update. Scott A. Brubaker, CTBS Director, Division of Human Tissues Office of Tissues and Advanced Therapies CBER/FDA FDA Update Scott A. Brubaker, CTBS Director, Division of Human Tissues Office of Tissues and Advanced Therapies CBER/FDA 13 th Annual FDA and the Changing Paradigm for HCT/P Regulation February 13, 2017

More information

Strategies for Ensuring Integrity for Medical Tissues and Devices

Strategies for Ensuring Integrity for Medical Tissues and Devices Strategies for Ensuring Integrity for Medical Tissues and Devices RFID technologies offer near-real time safe and secure item-level visibility By Joe Pleshek Business Development Director Terso Solutions,

More information

South Carolina Donor Registry Q & A

South Carolina Donor Registry Q & A South Carolina Donor Registry Q & A How do I become a registered organ and tissue donor? There are several ways to register your legal consent to be a donor: 1.) At any SCDMV office or on the SCDMV web

More information

The Science of Stem Cell Therapy

The Science of Stem Cell Therapy The Science of Stem Cell Therapy AVM Biotechnology City Centre Building 1420 Fifth Avenue, Suite 2650 Seattle, WA 98101 206-906-9922 www.avmbiotech.com Copyright 2008 AVM Biotechnology, LLC speaker disclosure

More information

Sponsoring an IND? Ignorance is Not Always Blissful

Sponsoring an IND? Ignorance is Not Always Blissful Translational Science 2013 Navigating The FDA Regulatory Landscape April 19, 2013 Washington D.C. Sponsoring an IND? Ignorance is Not Always Blissful Lisa A. Speicher, Ph.D Director, Clinical Trials Office

More information

Stem Cells & Neurological Disorders. Said Ismail Faculty of Medicine University of Jordan

Stem Cells & Neurological Disorders. Said Ismail Faculty of Medicine University of Jordan Stem Cells & Neurological Disorders Said Ismail Faculty of Medicine University of Jordan Outline: - Introduction - Types & Potency of Stem Cells - Embryonic Stem Cells - Adult Stem Cells - ipscs -Tissue

More information

Osteobiologic B O N E G R A F T I N G S O L U T I O N S

Osteobiologic B O N E G R A F T I N G S O L U T I O N S Osteobiologic BONE GRAFTING SOLUTIONS The AlloSource Advantage Delivering Quality and Safety * Allografts labeled Sterile R are aseptically processed and packaged and then subjected to gamma irradiation.

More information

Special Report. medicine? Peter Marks, M.D., Ph.D., and Scott Gottlieb, M.D.

Special Report. medicine? Peter Marks, M.D., Ph.D., and Scott Gottlieb, M.D. The new england journal of medicine Special Report Balancing Safety and Innovation for Cell-Based Regenerative Medicine Peter Marks, M.D., Ph.D., and Scott Gottlieb, M.D. Regenerative medicine is a field

More information

Regulatory Schema for Blood Transfusion Microbiotal transplant conference

Regulatory Schema for Blood Transfusion Microbiotal transplant conference Regulatory Schema for Blood Transfusion Microbiotal transplant conference Baltimore, 3-4 December 2015 John R. Hess, MD, MPH, FACP, FAAAS Professor of Laboratory Medicine Medical Director, Transfusion

More information

True Confessions: Ancillary Materials in a Cell Processing Lab. Cell Processing Section, DTM, CC, NIH David Stroncek, MD Chief, CPS, DTM, CC

True Confessions: Ancillary Materials in a Cell Processing Lab. Cell Processing Section, DTM, CC, NIH David Stroncek, MD Chief, CPS, DTM, CC True Confessions: Ancillary Materials in a Cell Processing Lab Cell Processing Section, DTM, CC, NIH David Stroncek, MD Chief, CPS, DTM, CC Mission Provide cellular and gene therapy products and services

More information

SNC2D BIOLOGY 3/31/2013. TISSUES, ORGANS & SYSTEMS OF L Stem Cells & Meristematic Cells (P.40-41) Specialized Cells. Stem Cells

SNC2D BIOLOGY 3/31/2013. TISSUES, ORGANS & SYSTEMS OF L Stem Cells & Meristematic Cells (P.40-41) Specialized Cells. Stem Cells SNC2D BIOLOGY TISSUES, ORGANS & SYSTEMS OF L & Meristematic Cells (P.40-41) Specialized Cells The cell theory states that all cells come from pre-existing cells. Every cell that makes up an animal s body

More information

HCT/P Regulation vs 361 Products

HCT/P Regulation vs 361 Products HCT/P Regulation - 351 vs 361 Products Presented by: Paul Gadiock February 15, 2017 Arent Fox LLP Washington, DC New York, NY Los Angeles, CA San Francisco, CA 1 Presentation Overview Introduction Public

More information

Cell Therapy Services Your Product. Our Passion.

Cell Therapy Services Your Product. Our Passion. Pharma&Biotech Cell Therapy Services Your Product. Our Passion. Complete Portfolio of Services for cgmp Manufacturing of Cell-based Products Pharma&Biotech Cell Therapy Services for cgmp Manufacturing

More information

High Quality or Poor Quality DB

High Quality or Poor Quality DB The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug Information Association, Inc. ( DIA ), its directors, officers,

More information

SECTION L QUALITY ASSURANCE. 1) designating and managing quality control functions, including:

SECTION L QUALITY ASSURANCE. 1) designating and managing quality control functions, including: NT-L1.000 QUALITY ASSURANCE PROGRAM All NADOs shall have a QA Program. Current (2 nd Edition) NT-L1.100 BASIC ELEMENTS SECTION L QUALITY ASSURANCE The QA program shall include, at a minimum: 1) designating

More information

Pathogen Inactivation and Blood Safety in the US. Richard Benjamin, MD PhD Chief Medical Officer Washington, D.C.

Pathogen Inactivation and Blood Safety in the US. Richard Benjamin, MD PhD Chief Medical Officer Washington, D.C. Pathogen Inactivation and Blood Safety in the US Richard Benjamin, MD PhD Chief Medical Officer Washington, D.C. Conflict of Interest The American Red Cross is participating in a clinical trial of the

More information

Stem Cells Canadian Perspective

Stem Cells Canadian Perspective Stem Cells Canadian Perspective John Laffey Critical Illness and Injury Research Centre, Keenan Research Centre, St Michael s Hospital. Departments of Anesthesia, Physiology and Interdepartmental Division

More information

Stem Cell Research From Bench to Bedside

Stem Cell Research From Bench to Bedside Stem Cell Research From Bench to Bedside Stem Cell Dialogues Jan A. Nolta, Ph.D. Professor, Internal Medicine Director, UC Davis Institute for Regenerative Cures October 26, 2010 Stem Cells at UC Davis

More information

ISBT 128 coding system and the Single European Code: Introduction. Presented by: Jessy Lardon

ISBT 128 coding system and the Single European Code: Introduction. Presented by: Jessy Lardon ISBT 128 coding system and the Single European Code: Introduction Presented by: Jessy Lardon Single European Code (= SEC) The SEC is the unique identifier applied to tissues and cells distributed in the

More information

IRB USE ONLY Approval Date: September 10, 2013 Expiration Date: September 10, 2014

IRB USE ONLY Approval Date: September 10, 2013 Expiration Date: September 10, 2014 Approval : September 10, 2013 Expiration : September 10, 2014 DESCRIPTION: You are invited to donate your excess sperm and/or testicular biopsy material, as well as your somatic cells (ordinary body cells

More information

10/17/ /17/2017

10/17/ /17/2017 Apheresis Objectives: Explain the concept of cell centrifugation Explain the concept of extracorporeal volume Name 2 methods of venous access for apheresis 1 What is Apheresis? Elements: Whole blood removal

More information

IS HE SPEAKING ENGLISH? cgmp: : Current Good Manufacturing Practice PHS Act: : Public Health Service Act CFR: : Code of Federal Regulations CP: : Comp

IS HE SPEAKING ENGLISH? cgmp: : Current Good Manufacturing Practice PHS Act: : Public Health Service Act CFR: : Code of Federal Regulations CP: : Comp PREPARING FOR AN FDA INSPECTION August 11, 2011 Kip J. Hanks, Investigator Biologics National Expert FDA Division of Domestic Field Investigations 1 IS HE SPEAKING ENGLISH? cgmp: : Current Good Manufacturing

More information

Cell Therapy Liaison Meeting, January 27, 2006

Cell Therapy Liaison Meeting, January 27, 2006 Cell Therapy Liaison Meeting, January 27, 2006 Bethesda, MD, Summary Attendees were welcomed by Stephen J. Noga, MD, PhD, ISCT FDA Liaison and the meeting was called to order at 8:15am. HIV and HCV NAT

More information

Quality Manual. Quality Manual. Vera Bioscience / Anu Life Sciences. April 2018

Quality Manual. Quality Manual. Vera Bioscience / Anu Life Sciences. April 2018 Quality Manual Vera Bioscience / Anu Life Sciences April 2018 Page 1 of 15 TABLE OF CONTENTS Quality Manual Page 1. Company Overview 3 2. References 3 3. Exemptions, Alternatives and Variances 3 4. General

More information

Martha A Wells, MPH Division of Human Tissues OCTGT, CBER, FDA. Pharma Conference HCT/P Meeting January 24, 2007 San Antonio, TX

Martha A Wells, MPH Division of Human Tissues OCTGT, CBER, FDA. Pharma Conference HCT/P Meeting January 24, 2007 San Antonio, TX Guidance for Industry: Certain Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) Recovered From Donors Who Were Tested For Communicable Diseases Using Pooled Specimens or Diagnostic

More information

Error Management and BPD Reporting for the Transfusion Service. Mary A Lieb MT(ASCP)SBB, CQA(ASQ) Director, Quality Source Blood Systems,

Error Management and BPD Reporting for the Transfusion Service. Mary A Lieb MT(ASCP)SBB, CQA(ASQ) Director, Quality Source Blood Systems, Error Management and BPD Reporting for the Transfusion Service Mary A Lieb MT(ASCP)SBB, CQA(ASQ) Director, Quality Source Blood Systems, Objectives Define biological product deviation Explain what constitutes

More information

Instructions for Hematopoietic Stem Cell Transplant (HSCT) Infusion Form 2006

Instructions for Hematopoietic Stem Cell Transplant (HSCT) Infusion Form 2006 Instructions for Hematopoietic Stem Cell Transplant (HSCT) Infusion Form 2006 E-mail comments regarding the content of the CIBMTR Forms Instruction Manual to: CIBMTRFormsManualComments@nmdp.org. Comments

More information

MD Anderson Cancer Center Department of Blood and Marrow Transplantation Cell Therapy Laboratory

MD Anderson Cancer Center Department of Blood and Marrow Transplantation Cell Therapy Laboratory MD Anderson Cancer Center Department of Blood and Marrow Transplantation Cell Therapy Laboratory PRODUCTS AND PROCEDURES ~ 1500 products processed per year ~ 700 products infused per year ~ > 800 Cord

More information

The critical role of shipping & logistics in the commercialization of cord blood therapies

The critical role of shipping & logistics in the commercialization of cord blood therapies LATEST ADVANCES IN CORD BLOOD APPLICATIONS & COMMERCIALIZATION INNOVATOR INSIGHT The critical role of shipping & logistics in the commercialization of cord blood therapies David Murphy is a 30 year veteran

More information